Answers are grounded in this paper and cite their sources.
Review reveals haematological adverse events and management strategies during checkpoint inhibitor therapy, highlighting safety considerations for drug rechallenge.
Summary The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this ‘nutshell review’, we summarize the most common haematological immune‐related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and address current evidence regarding ICI rechallenge.
No takes yet. Share an insight, caveat, or question.
Leaf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: